undamentalytics Newsletter
Sign in

Ceribell, Inc. (CBLL) stock

Add to watchlist

Add holding +

NASDAQ: CBLL Nasdaq Health Care Equipment Next results ~November 3, 2026

C Fundamentals grade

Ceribell, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Ceribell, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Ceribell, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 10 selling0 purchases and 100 sales by directors and officers, last 12 monthsInsider trades
  • Funds72 adding, 49 cuttingOf 31 active managers that changed their stake, 20 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Ceribell files

Where Ceribell stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $102m, up 31.7% on a year earlier, slower than the 32.9% growth a quarter earlier. That growth ranks 19 of 103 among the health care equipment companies we cover. Free-cash-flow margin fell to -53.7% from -49.9% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 4 of our 6 financial-health checks.

Our model value for Ceribell is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Ceribell, Inc.'s trailing-twelve-month revenue grew 31.7% year on year, with a free-cash-flow margin of -53.7%. Where it stands out: gross margin of 88.9% ranks 5 of 123 health care equipment companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 31.7% (-1.2pp vs the prior quarter), the 4th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 31.7% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.0bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 3 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -68.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -53.7% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 16.1% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Volatile shares. Over the past year the shares showed annualised volatility of 51% and a beta of 1.2 against the S&P 500.
  • Insiders selling. 10 insiders sold $23M of stock over the past 365 days and none bought (78% under pre-set trading plans).

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
-$0.40 against an average estimate of -$0.46: beat by 11.9%
Revenue
$28m, up 32.5% on a year earlier
Share reaction
+13.3% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Guidance given
revenue guidance $114m to $117m (full year 2026)
Next report
November 3, 2026; average EPS estimate -$0.52

Ceribell's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.4%
  • 1 week-0.3%
  • 1 month+13.8%
  • This year+22.9%
  • 1 year+136.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$102M
Operating margin
-68.6%
Net margin
-64.7%
EPS (TTM, diluted)
$-1.76

Growth

Revenue growth
+31.7%
Change in growth rate
−1.2 pts

Cash

Free cash flow (TTM)
-$54.7M
FCF margin
-53.7%
Stock pay % of revenue
16.1%

Earnings

Last results
August 10, 2026
Next results (est.)
November 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Ceribell, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Ceribell, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.7%: the 10-year Treasury yield (4.9%) plus a beta of 0.83 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.7 ~$1.4–$4.0 Left out: out of range vs price (0.10x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.7 ~$5.1–$18 Left out: out of range vs price (0.17x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$1.6 ~$0.9–$2.4 Left out: out of range vs price (0.06x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Ceribell, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025Now
Share price$25.88$21.93$26.96
Market value$928m$801m$1.0bn
+ Net debt (− = net cash)−$175m−$21m−$13m
Enterprise value$753m$781m$996m
Multiples
Price / sales 14.2x9.0x9.9x
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $29m and EPS of −$0.52 (range −$0.55 to −$0.48) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.96 −35% $115m +30%
Next −$1.61 +18% $147m +27%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +16.7% on 90 days ago. In the last 30 days, 0 analysts raised Ceribell, Inc.'s forecast and 4 cut it.

Consensus EPS forecast Ceribell, Inc., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.68 Current fiscal year, 60 days ago: −$1.68 Current fiscal year, 30 days ago: −$1.96 Current fiscal year, 7 days ago: −$1.96 Current fiscal year, Now: −$1.96 −$1.96 Next fiscal year, 90 days ago: −$1.10 Next fiscal year, 60 days ago: −$1.10 Next fiscal year, 30 days ago: −$1.54 Next fiscal year, 7 days ago: −$1.61 Next fiscal year, Now: −$1.61 −$1.61

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.68−$1.10
60 days ago −$1.68−$1.10
30 days ago −$1.96−$1.54
7 days ago −$1.96−$1.61
Now −$1.96−$1.61

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.46 −$0.40 +11.9%
Mar 2026 −$0.39 −$0.38 +3.6%
Dec 2025 −$0.41 −$0.36 +12.7%
Sept 2025 −$0.41 −$0.37 +10.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 10, 2026
  • revenue guidance full year 2026 $114m to $117m Raised
    “Ceribell is raising its revenue guidance for the full year 2026 to a range of $114 million to $117 million, representing growth of approximately 28% to 31% over the Company's prior year revenue.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

8 analysts, Oct 2026
Buy8100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026178
  2. Sep 2026178
  3. Aug 2026178
  4. Jul 2026178

Counts of recommendations published by analysts covering Ceribell, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.6%
of tradable shares
Days to cover
5.05
at average volume
Short interest, 1 month
+19%
to October 15, 2026
Held by institutions
91%
of shares
Held by insiders
11.8%
of shares
Employees
327
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
CBLL−15%+23%
Industry peers (median)−16%−15%
S&P 500+18%+11%
Months that ended higher
CBLL42%55%
S&P 50075%46%
Largest fall from a high during the year
CBLL−58%−31%
S&P 500−19%−9%

Worst fall since October 11, 2024: 64% from December 6, 2024 to November 4, 2025. Getting back needed a 177% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$10.92 – $27.82
From 52-week high
−3.1%
vs 50-day average
+7.9%
vs 200-day average
+29.6%
Volatility (1 year)
51%
Beta vs S&P 500
1.18

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 6 down
typical move ±7.5%
After a week
3 up, 5 down
typical move ±15.2%
After a month
4 up, 4 down
typical move ±21.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 +13.3% −0.3% +29.7% +29.8%
May 11, 2026 −17.1% +0.1% −17.9% −9.0%
February 24, 2026 −5.2% +1.6% −12.3% −6.1%
November 4, 2025 +3.9% −0.8% +10.4% +68.9%
August 5, 2025 −16.1% +0.3% −23.2% −19.0%
May 8, 2025 −0.2% +0.6% +9.9% +11.2%
February 25, 2025 −0.9% −0.4% −6.6% −23.0%
November 12, 2024 −3.5% −0.3% −11.5% +1.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Ceribell, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Ceribell, Inc.
$40M $60M $80M $100M $120M FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue (TTM), FY24 Q2: $54.5M Revenue (TTM), FY24 Q3: $60M Revenue (TTM), FY24 Q4: $65.4M Revenue (TTM), FY25 Q1: $71.5M Revenue (TTM), FY25 Q2: $77.4M Revenue (TTM), FY25 Q3: $82.8M Revenue (TTM), FY25 Q4: $89.1M Revenue (TTM), FY26 Q1: $95.1M Revenue (TTM), FY26 Q2: $102M $102M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $54.5M
FY24 Q3 $60M
FY24 Q4 $65.4M
FY25 Q1 $71.5M
FY25 Q2 $77.4M
FY25 Q3 $82.8M
FY25 Q4 $89.1M
FY26 Q1 $95.1M
FY26 Q2 $102M
Revenue growth, TTM YoY Ceribell, Inc.
30% 35% 40% 45% FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 Revenue growth, TTM YoY, FY25 Q2: 42.2% Revenue growth, TTM YoY, FY25 Q3: 37.9% Revenue growth, TTM YoY, FY25 Q4: 36.1% Revenue growth, TTM YoY, FY26 Q1: 32.9% Revenue growth, TTM YoY, FY26 Q2: 31.7% 31.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY25 Q2 42.2%
FY25 Q3 37.9%
FY25 Q4 36.1%
FY26 Q1 32.9%
FY26 Q2 31.7%
Operating margin (TTM) Ceribell, Inc.
-80% -60% -40% -20% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY24 Q2: -59.6% Operating margin (TTM), FY24 Q3: -58.6% Operating margin (TTM), FY24 Q4: -60.7% Operating margin (TTM), FY25 Q1: -63.6% Operating margin (TTM), FY25 Q2: -67.1% Operating margin (TTM), FY25 Q3: -68.5% Operating margin (TTM), FY25 Q4: -65.6% Operating margin (TTM), FY26 Q1: -68.3% Operating margin (TTM), FY26 Q2: -68.6% -68.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -59.6%
FY24 Q3 -58.6%
FY24 Q4 -60.7%
FY25 Q1 -63.6%
FY25 Q2 -67.1%
FY25 Q3 -68.5%
FY25 Q4 -65.6%
FY26 Q1 -68.3%
FY26 Q2 -68.6%
FCF margin (TTM) Ceribell, Inc.
-60% -40% -20% 0% FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 FCF margin (TTM), FY24 Q3: -55.3% FCF margin (TTM), FY24 Q4: -55.6% FCF margin (TTM), FY25 Q1: -53.5% FCF margin (TTM), FY25 Q2: -49.9% FCF margin (TTM), FY25 Q3: -49.5% FCF margin (TTM), FY25 Q4: -46.7% FCF margin (TTM), FY26 Q1: -52.0% FCF margin (TTM), FY26 Q2: -53.7% -53.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q3 -55.3%
FY24 Q4 -55.6%
FY25 Q1 -53.5%
FY25 Q2 -49.9%
FY25 Q3 -49.5%
FY25 Q4 -46.7%
FY26 Q1 -52.0%
FY26 Q2 -53.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 45 65 89 102
Gross profit 38 57 78 91
EBITDA −29 −39 −57 −69
Operating income −30 −40 −58 −70
Net income −29 −40 −53 −66
Diluted EPS −$1.85 −$1.13 −$1.46 −$1.76
Growth (year on year)
Revenue — +44.7% +36.1% +31.7%
Margins
Gross margin 84.4% 86.7% 87.9% 88.9%
EBITDA margin −64.6% −58.9% −64.1% −67.6%
Operating margin −66.4% −60.7% −65.6% −68.6%
Net margin −65.1% −61.8% −60.0% −64.7%
Free-cash-flow margin −66.6% −55.6% −46.7% −53.7%
Cash flow
Cash from operations −29 −35 −41 −54
Capital spending 1 1 1 1
Free cash flow −30 −36 −42 −55
Stock-based pay 3 5 12 16
Free cash flow after stock pay −33 −42 −54 −71
Balance sheet
Cash 34 194 40 33
Total debt 12 20 20 20
Net debt (negative = net cash) −23 −175 −21 −13
Diluted shares 16m 36m 37m 37m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $166m
Short-term assets $158mLonger-term assets $9m
What it owes, and who funded it · $166m
Short-term liabilities $17mLonger-term liabilities $21mShareholders' equity $128m
  • Short-term assets cover short-term liabilities $158m of assets due within a year against $17m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $158m short-term assets against $21m of longer-dated liabilities.
  • More cash than debt $33m of cash against $20m of debt.
  • Debt below 40% of shareholders' equity Debt is 16% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$54m of operating cash flow against $20m of debt.
  • Operating profit covers interest at least five times over Operating income of −$70m against $2m of interest.

From Ceribell, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
22.5%
of revenue
Days sales outstanding
57 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated CBLL DCTH XTNT SMTI OWLT IRMD Median
Revenue, last 12 months $102m $95m $110m $110m $115m $89m $99m
Revenue growth, last 12 months 31.7% 35.8% −14.3% 13.0% 28.2% 11.0% 9.2%
Revenue growth, 3-year average — 230.8% 17.3% 22.6% 29.3% 12.4% 13.5%
Revenue growth, latest quarter 32.5% 20.6% −35.0% 9.0% 29.9% 14.2% 10.2%
Gross margin 88.9% 87.1% 59.4% 93.0% 54.8% 75.5% 61.2%
Operating margin −68.6% −1.9% −9.6% 7.7% −6.3% 32.3% −8.5%
Operating margin, 3-year average −65.1% −99.4% −7.3% 2.2% −17.9% 31.0% −17.9%
Net margin −64.7% 0.6% −10.2% −29.2% −7.7% 26.8% −12.0%
Cash from operations / revenue −53.0% 20.5% 0.5% 5.2% −6.8% 30.4% −1.9%
Free-cash-flow margin −53.7% 18.3% −0.6% 4.1% −7.4% 29.3% −3.9%
Free-cash-flow margin, 3-year average — −80.5% −6.2% −0.1% −14.1% 24.2% −7.0%
Stock pay / revenue 16.1% 21.2% 2.7% 4.5% 11.2% 3.3% 6.1%
Change in share count — 10.8% 4.0% 0.3% 72.6% 0.3% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 31.7% 9.1% 24 of 129
Change in growth rate Growth -1.2pp -0.6pp 79 of 129
Gross margin Profitability 88.9% 61.9% 5 of 123
Operating margin Profitability -68.6% -8.3% 94 of 132
Net margin Profitability -64.7% -12.0% 94 of 133
Free-cash-flow margin Cash generation -53.7% -3.4% 97 of 128
Stock pay as % of revenue Cash generation 16.1% 6.1% 92 of 123
Long-term debt as % of assets Balance sheet 12.0% 24.2% 27 of 87
Days sales outstanding Balance sheet 57 days 57 days 62 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $67.3M 75.6% ▲ 34.5%
Subscription $21.7M 24.4% ▲ 41.4%

From Ceribell, Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$594M
Institutions reporting
123
Shares held vs prior quarter
▲ 2.2%
Positions opened / closed
16 / 13

Top buyers and sellers, Q2 2026: 72 institutions bought and 49 sold ; the biggest buyer was FMR LLC (+841K shares) and the biggest seller Kcm Capital Inc (−275K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $111M 5.7M 18.6% ▲ 17.3%
Tpg Gp A, LLC $73.2M 3.8M 12.3% ▼ 5.2%
Red Tree Management, LLC $42.9M 2.2M 7.2% 0.0%
Blackrock, Inc. $37.7M 1.9M 6.3% ▲ 6.8%
Vanguard Capital Management LLC $22M 1.1M 3.7% ▼ 0.6%
Kcm Capital Inc $21.9M 1.1M 3.7% ▼ 19.6%
Federated Hermes, Inc. $18.3M 940K 3.1% 0.0%
Franklin Resources Inc $17.9M 918K 3.0% ▲ 13.4%
Adage Capital Partners Gp, L.L.C. $17.5M 900K 2.9% ▲ 18.9%
Bank Of New York Mellon Corp $17.4M 896K 2.9% ▼ 22.8%
Timessquare Capital Management, LLC $15.2M 781K 2.6% ▲ 8.9%
Millennium Management LLC $14.1M 727K 2.4% ▲ 31.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Ceribell, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $22.9M 100 trades by 10 insiders · 78% under pre-set plans
Net ▼ $22.9M net selling
Insider Date Trade Shares Price Value
Woo Raymond Chief Technology Officer October 1, 2026 Sell pre-set plan 4,887 $24.38 $119,145
Blumberg Scott Chief Financial Officer September 15, 2026 Sell pre-set plan 846 $25.00 $21,150
Chao Xingjuan President and CEO September 15, 2026 Sell pre-set plan 20,846 $25.03 $521,775
Woo Raymond Chief Technology Officer September 8, 2026 Sell pre-set plan 4,887 $24.33 $118,901
Foehr David Senior VP, Finance and PAO September 8, 2026 Sell pre-set plan 7,500 $24.25 $181,875
Foehr David Senior VP, Finance and PAO September 8, 2026 Sell pre-set plan 1,755 $24.26 $42,576
Blumberg Scott Chief Financial Officer September 2, 2026 Sell pre-set plan 652 $25.00 $16,300
Chao Xingjuan President and CEO September 2, 2026 Sell pre-set plan 39,540 $24.61 $973,079
Foehr David Senior VP, Finance and PAO August 24, 2026 Sell pre-set plan 859 $23.95 $20,573
Chao Xingjuan President and CEO August 21, 2026 Sell 6,068 $24.02 $145,753
Blumberg Scott Chief Financial Officer August 21, 2026 Sell 1,521 $24.02 $36,534
Woo Raymond Chief Technology Officer August 21, 2026 Sell 1,979 $24.02 $47,536

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 3, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 11, 2026
  • February 24, 2026
  • November 4, 2025
  • August 5, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Ceribell, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Ceribell, Inc. in brief

What does Ceribell, Inc. do?
Ceribell, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Ceribell, Inc.'s stock ticker?
Ceribell, Inc. trades under the ticker CBLL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Ceribell, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Ceribell, Inc. reported revenue of $102M, 31.7% higher than a year earlier, according to its SEC filings.
What is Ceribell, Inc.'s free cash flow?
Ceribell, Inc.'s free-cash-flow margin is -53.7% of revenue over the trailing twelve months, ranking 97 of the 128 health care equipment companies we cover.
Who are Ceribell, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Tpg Gp A, LLC and Red Tree Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Ceribell, Inc.'s market cap?
On November 2, 2026, Ceribell, Inc.'s market capitalisation was about $1B and net debt of -$12.7M. Market figures come from third-party market data and may be delayed.
How much debt does Ceribell, Inc. have?
Ceribell, Inc.'s debt-to-equity ratio is 15.6%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Ceribell, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Ceribell, Inc. are Delcath Systems, Inc., Xtant Medical Holdings, Inc., Sanara Medtech Inc., Owlet, Inc. and Iradimed Corp. The side-by-side comparison below sets their revenue, margins and growth against Ceribell, Inc.'s.
Are insiders buying or selling Ceribell, Inc. stock?
Over the last 12 months, Ceribell, Inc.'s directors and officers reported 0 open-market purchases and 100 sales on Form 4. The insider trading page charts every trade.
When is Ceribell, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Ceribell, Inc. announces its own schedule.